XtalPi and AWS: Changing How Medications Are Discovered

XtalPi, a leader in AI-driven drug research, has teamed up with Amazon Web Services (AWS) to speed up the process of developing new medicines. This partnership is reshaping how researchers tackle the challenge of identifying and testing promising drug candidates, offering new tools that combine artificial intelligence, robotics, and cloud computing.

At AWS re:Invent 2024 in Las Vegas, XtalPi confirmed its decision to use AWS as its primary cloud provider. The company’s platforms rely on cutting-edge technologies like quantum computing and AI to model molecules, identify promising compounds, and streamline research workflows. By working with AWS, XtalPi says it can deliver faster results while maintaining strict data security and compliance standards.

“Our collaboration with AWS allows us to build scalable and secure platforms that advance drug discovery at a much faster pace,” said Yongpan Chen, head of XtalPi’s Digitalisation Department.

 

Smarter, Faster Research with PatSight

One of the standout results of this partnership is PatSight, a patent analysis platform developed with the International Digital Economy Academy (IDEA). PatSight uses AWS’s Amazon Bedrock service to process huge amounts of chemical and patent data in hours instead of weeks.

The platform can examine thousands of molecular structures and identify whether they’re already covered by patents with over 95% accuracy. This kind of speed and precision means researchers can spend less time navigating legal red tape and more time focusing on the science.

More Efficient Tools for Researchers

AWS tools are also helping XtalPi improve efficiency across its operations. The company’s software developers use Amazon Q Developer to quickly write and refine code, while Amazon Elastic Kubernetes Service (EKS) and EC2 Spot Instances offer a scalable way to run complex workloads. These tools have significantly reduced the costs of running XtalPi’s platforms, allowing the company to allocate resources more effectively.

XtalPi’s integration of Amazon SageMaker — a machine learning tool — into its drug discovery platform has also been a game changer. SageMaker helps XtalPi’s team train and deploy AI models more quickly, speeding up the process of identifying viable drug candidates.

A Growing Impact

XtalPi’s work already supports 16 of the world’s top 20 pharmaceutical companies. As the demand for more affordable and efficient drug development grows, partnerships like the one between XtalPi and AWS show how technology can address some of the industry’s biggest challenges.

“AWS’s infrastructure is helping us transform the way we approach research,” said Deepak Nair, director of Healthcare and Life Sciences at AWS. “By reducing costs and improving success rates, these tools allow researchers to focus on what matters most — developing better treatments for patients.”

By combining cutting-edge technology with robust cloud infrastructure, XtalPi and AWS are setting new standards for speed, efficiency, and precision in the pharmaceutical industry. Their work is a glimpse into the future of medicine, where technology plays an even bigger role in shaping outcomes.

Read next: Transforming Healthcare in Africa with Technology